Long-Term Outcomes of Cervical Disc Replacement and Anterior Cervical Discectomy and Fusion: A Review of FDA IDE Trials With Real-World Comparison

Abstract

Study design

Retrospective comparative cohort study.

Objective

To validate FDA IDE–sponsored trial findings on cervical disc replacement (CDR) and anterior cervical discectomy and fusion (ACDF) by comparing reoperation outcomes with real-world data.

Methods

Patients undergoing one- or two-level ACDF or CDR from 2010-2022 were identified in the PearlDiver (PD) database. FDA IDE trials were retrieved through review of databases. Subsequent surgeries and sample sizes were extracted at 2-, 4-, 5-, 7-, and 10-year intervals. Event rates were calculated as reoperations divided by patients at risk, and survival probabilities as S(t) = 1−event rate. Kaplan–Meier–style survival curves were reconstructed using the Guyot algorithm with a monotonicity constraint. Pooled FDA survival probabilities were weighted by number at risk. Hazard ratios (HRs) were derived from log-transformed survival probabilities, and statistical significance was tested using Pearson’s chi-square or Fisher’s exact test. Analyses were stratified by surgical level (1- vs 2-level) and procedure type (CDR vs ACDF).

Results

In total, 277 146 ACDF and 25 957 CDR patients from PD and 46 FDA trials were analyzed. CDR reoperation risks were similar between FDA and PD cohorts, though differences were significant at 2-, 7-, and 10-year follow-up for 1-level procedures. ACDF reoperation risks were consistently and significantly lower in PD (eg, HR 0.4 at 7 years).

Conclusion

Reoperation risks for CDR were broadly comparable, while ACDF outcomes were superior in practice compared with trials. These differences may reflect trial selection bias or stricter adjudication of ACDF outcomes. Validation against real-world data supports long-term safety assessment and personalized surgical decision-making.

Keywords

cervical disc replacement anterior cervical discectomy and fusion FDA trials and real-world outcome

Introduction

Degenerative cervical spine disease is a common disorder characterized by neck pain, radiculopathy, and myelopathy.¹ Early surgical treatment involved laminectomy and posterior forminotomy, however, due to anatomical limitations in effectively addressing centrally or paracentrally located discs, anterior cervical discectomy and fusion (ACDF) emerged as the favorable method by the mid-20^th century.² ACDF is now regarded as the gold standard for degenerative cervical disc disease.³

To address the limitations of ACDF, particularly reduced spinal mobility and adjacent segment disease (ASD), cervical disc replacement (CDR) was developed as a motion-preserving alternative. Since its commercial debut in 2007,⁴ CDR use has grown significantly.^5-8 Currently, 9 devices are approved for single-level CDR, with 3 also approved for two-level procedures.^4,9-17 Clinical trials have shown CDR to be non-inferior to ACDF, with better long-term outcomes in pain relief, function, and lower rates of ASD and revision surgery.

CDR approvals were based on FDA investigational device exemption (IDE) trials, which were non-blinded, multicenter randomized controlled trials.¹⁸ However, concerns have been raised about the rigour of these studies due to limitations in design, bias, and post-approval oversight.^19,20 Although post-approval studies (PAS) are required,¹⁸ they often suffer from small sample sizes, poor follow-up, and limited generalizability.²¹

Given these limitations, this study aims to validate the findings of FDA IDE-sponsored trials by comparing long-term outcomes of CDR and ACDF using real-world data from a national database. Specifically, this study will assess subsequent surgery rates reported in the FDA trials and compare them to those observed in a large, nationally representative cohort over the last decade.

Methods

Data Source and Study Population

This study utilized the PearlDiver (PD) Mariner Database (PearlDiver Technologies, Colorado Springs, CO, USA) to identify patients who underwent ACDF and CDR between 2010 and 2022. The PD database is a nationwide insurance claims database containing approximately 157 million de-identified patients, that includes demographic, diagnostic, and procedural data from various payer types across inpatient and outpatient settings. As the study relied on anonymized data, already published articles and was retrospective in nature, informed consent was waived, and institutional review board approval was not required.

Pubmed, Scopus and Cochrane databases were used to identify FDA-approved IDE trials on April 14, 2025.

Identification of Study Cohorts in PearlDiver

International Classification of Diseases (ICD), 9th (ICD-9) and 10th (ICD-10) editions, along with Current Procedural Terminology (CPT) codes, were utilized to identify patients (Supplemental Table 1). Specifically, patient records containing codes for one- or two-level ACDF and CDR procedures were queried. To exclude hybrid surgical constructs, patients in the ACDF group were removed if they had undergone CDR within 1 week of the index procedure. Similarly, patients in the CDR group were excluded if they had undergone ACDF within 1 week of the procedure. Patients in both study cohorts were also excluded if they had a history of prior cervical surgery before the index ACDF or CDR procedure. Additional exclusion criteria included patients under 18 years of age, those with less than 1 year of postoperative follow-up, and cases involving surgical indications related to trauma, malignancy, or infection. Patients were further categorized based on subsequent surgeries performed in the cervical region.

To simulate an intention-to-treat analysis similar to FDA IDE trials, only patients with complete follow-up data were included. For example, in the 2-year cohort, patients were included if their index surgery occurred between 2010 and 2020, as PD contains data through 2022, ensuring all patients could have full follow-up. Similarly, patients in the 3-year cohort were included if their index surgery occurred between 2010 and 2019; for the 4-year cohort, between 2010 and 2018; for the 5-year cohort, between 2010 and 2017; for the 7-year cohort, between 2010 and 2015; and for the 10-year cohort, between 2010 and 2012.

Identification of Study Cohorts in FDA IDE Trials

Pubmed, Scopus and Cochrane databases were queried since inception on April 14, 2025, using human participants and the English language as a search filter and (“Anterior Cervical Discectomy and Fusion” OR “ACDF” OR “Cervical Discectomy” OR “Fusion” OR “Cervical Spine Fusion” OR “Cervical Degenerative Disease” OR “Cervical Degeneration”) AND (“Cervical Disc Replacement” OR “CDR” OR “Cervical Total Disc Replacement” OR “CTDR” OR “Total Disc Replacement” OR “TDR” OR “Artificial Disc Replacement” OR “Cervical Arthroplasty” OR “Disc Arthroplasty” OR “Cervical Degenerative Disease” OR “Cervical Degeneration”) AND (“Randomized Controlled Trial” OR “RCT” OR “Randomized Study” OR “Clinical Trial” OR “Interventional Study”) as a search strategy. Our exclusion criteria included trials that compared devices not approved by the FDA for commercial distribution or that reported subsequent surgery rates beyond a 10-year follow-up period due to the small sample size available for comparison in the PD database. Duplicates were removed, and relevant full-text randomized controlled clinical trials (RCT) were screened for data collection following the title and abstract screening (Figure 1).

Figure 1.

Flow Chart for the Selection of FDA IDE Trials

Primary Endpoints

The primary aim of this study was to evaluate whether the outcomes, in terms of subsequent surgery required at the cervical region, reported across FDA IDE trials align with real-world outcomes (Table 1).

Table 1.

Subsequent Surgery Event In PearlDiver And FDA IDE Trials Cohort.

F/up period^a	Cohort^a	PD total patients	PD (n (%))	FDA trials total patients^b	FDA trials (n (%))^b	I^2c
2-year	1-Level CDR	18 879	588 [3.11%]	3013	127 [4.22%]	88.7%
	Z-statistic	−3.029	−3.029
	2-Level CDR	3057	105 [3.43%]	825	33 [4.0%]	1.3%
	Z-statistic	−0.749	−0.749
	1-Level ACDF	156 501	6129 [3.91%]	2696	199 [7.38%]	48.5%
	Z-statistic	−8.473	−8.473
	2-Level ACDF	90 717	4005 [4.41%]	643	69 [10.73%]	0%
	Z-statistic	−6.915	−6.915
3-year	2-Level CDR	2387	93 [4.1%]	234	7 [3%]	-
	Z-statistic	0.823	0.823
	2-Level ACDF	81 532	4393 [5.4%]	105	14 [13.3%]	-
	Z-statistic	−3.152	−3.152
4-year	1-Level CDR	13 616	626 [4.6%]	530	30 [5.66%]	59.1%
	Z-statistic	−1.081	−1.081
	2-Level CDR	1673	87 [5.31%]	225	9 [4.0%]	-
	Z-statistic	0.734	0.734
	1-Level ACDF	125 474	6970 [5.55%]	434	49 [11.29%]	0%
	Z-statistic	−4.661	−4.661
	2-Level ACDF	70 627	4420 [6.26%]	105	16 [15.24%]	-
	Z-statistic	−3.272	−3.272
5-year	1-Level CDR	11 128	568 [5.10%]	1769	116 [6.56%]	69.4%
	Z-statistic	−2.380	−2.380
	2-Level CDR	1038	52 [5.76%]	459	33 [7.19%]	0%
	Z-statistic	−1.571	−1.571
	1-Level ACDF	111 007	6839 [6.16%]	1528	189 [12.37%]	68.2%
	Z-statistic	−8.856	−8.856
	2-Level ACDF	61 445	4278 [6.96%]	210	44 [20.95%]	0%
	Z-statistic	−6.469	−6.469
7-year	1-Level CDR	6848	420 [6.13%]	2023	235 [10.72%]	96.4%
	Z-statistic	−6.371	−6.371
	2-Level CDR	201	11 [8.96%]	868	70 [8.06%]	60%
	Z-statistic	−1.160	−1.160
	1-Level ACDF	80 735	5848 [7.24%]	1679	329 [18.04%]	23%
	Z-statistic	−14.066	−14.066
	2-Level ACDF	42 919	3493 [8.17%]	586	119 [20.31%]	71.5%
	Z-statistic	−8.776	−8.776
10-year	1-Level CDR	2190	153 [6.99%]	1028	92 [8.95%]	85.9%
	Z-statistic	−1.798	−1.798
	2-Level CDR	Small sample	-	209	25 [11.9%]	-
	1-Level ACDF	30 592	2569 [8.39%]	953	199 [20.88%]	93.4%
	Z-statistic	−11.066	−11.066
	2-Level ACDF	Small sample	-	188	51 [27.1%]	-

^aSome patients had more than 1 surgical procedure.

^bPooled subsequent surgery rate across FDA trials was compared with PD data.

^cRepresent heterogeneity across FDA trials.

Abbreviations: F/up = Follow-up period; FDA = Food and Drug Administration; PD = PearlDiver; n = number of events.

Statistical Analysis

All statistical analyses were performed using R (version 3.4.4). For each included FDA IDE trial and Pearl Diver (PD) cohort, the number of subsequent surgeries and total sample size were extracted at each reported follow-up interval (2, 4, 5, 7, and 10 years). Event rates were calculated as the number of subsequent surgeries divided by the number of patients at risk at that time point. Survival probabilities were then derived as S(t) = 1−event rate.

Table 2.

Demographics of PearlDiver Patients Cohort.

Characteristic	1-Level ACDF	2-Level ACDF	1-Level CDR	2-Level CDR
Number of participants	174 135	103 011	21 995	3962
Mean age (years)	53.7 ± 11.8	56.5 ± 10.7	46.06 ± 9.92	49.3 ± 9.8
ECI	3.6 ± 3.1	3.8 ± 3.1	2.75 ± 2.61	3.3 ± 2.7
Female	94 518	56 292	12 318	2174
Male	79 617	46 719	9677	1788
Myelopathy	61 503	43 707	4786	903
Radiculopathy	134 852	80 687	18 540	3363
Insurance: Commercial	133 537	77 565	19 093	3377
Insurance: Medicare	24 454	16 175	1001	233
Insurance: Medicaid	10 174	5919	1121	210
Osteoporosis	16 296	11 372	916	185

Abbreviation: ECI = Elixhauser Comorbidity Index.

Table 3.

Demographics of FDA Trials Patient Cohort.

Study name	Device name	Level	F/up period	Sites	CDR sample size	ACDF sample size	Mean age (Y)
Mummaneni 2007²⁵	Prestige ST	1	2	32	276	265	CDR: 43.3ACDF: 43.9
Burkus 2010²⁶	Prestige ST	1	5	32	276	265	CDR: 43.3ACDF: 43.9
Burkus 2014²⁷	Prestige ST	1	2 & 7	31	276	265	CDR: 43.3ACDF: 43.9
Murrey 2009²⁸	Prodisc C	1	2	13	103	106	CDR: 42.1ACDF: 43.5
Delamarter 2010²⁹	Prodisc C	1	4	13	103	106	CDR: 42.1ACDF: 43.5
Zigler 2013³⁰	Prodisc C	1	5	13	103	106	CDR: 42.1ACDF: 43.5
Janssen 2015³¹	Prodisc C	1	7	13	103	106	CDR: 42.1ACDF: 43.5
Heller 2009³²	Bryan	1	2	30	242	221	CDR: 44.4ACDF: 44.7
Sasso 2007³³	Bryan	1	2	3	56	59	CDR: 43ACDF: 46
Sasso 2011³⁴	Bryan	1	2 & 4	30	242	221	CDR: 44.4^aACDF: 44.7^a
Sasso 2017³⁵	Bryan	1	10	1	22	25	CDR: 44.4^aACDF: 44.7^a
Lavelle 2019³⁶	Bryan	1	10	30	242	221	CDR: 44.4ACDF: 44.7
Phillips 2013³⁷	PCM	1	2	24	218	185	CDR: 45.3ACDF: 43.7
Phillips 2015³⁸	PCM	1	5 & 7	24	218	185	CDR: 45.3^aACDF: 43.7^a
Hisey 2014³⁹	Mobi-C	1	2	23	164	81	CDR: 43.3ACDF: 44
Hisey 2015⁴⁰	Mobi-C	1	4	24	164	81	CDR: 43.3^aACDF: 44^a
Radcliff 2017⁴¹	Mobi-C	1 & 2	7	24	1-Level:1642-Level: 225	1-Level:812-Level:105	1-LevelCDR: 43.3ACDF: 442-LevelCDR: 45.3ACDF: 46.2
Davis 2013⁴²	Mobi-C	2	2	24	225	105	CDR: 45.3ACDF: 46.2
Davis 2015⁴³	Mobi-C	2	4	24	225	105	CDR: 45.3ACDF: 46.2
Radcliff 2016⁴⁴	Mobi-C	2	5	24	225	105	CDR: 45.3ACDF: 46.2
Vaccaro 2013⁴⁵	Secure-C	1	2	18	236	144	CDR: 43.4ACDF: 44
Vacarro 2018⁴⁶	Secure-C	1	7	18	236	144	CDR: 43.4^aACDF: 44^a
Gornet 2017⁴⁷	Prestige LP	2	2	30	209	180	CDR: 47.1ACDF: 47.3
Gornet 2016⁴⁸	Prestige LP	1	7	20	280	265	CDR: 44.5ACDF: 43.9
Gornet 2019⁴⁹	Prestige LP	1	2, 5, 7 & 10	20	280	265	CDR: 44.5^aACDF: 43.9^a
Lanman 2017⁵⁰	Prestige LP	2	7	30	209	180	CDR: 47.1ACDF: 47.3
Gornet 2019⁵¹	Prestige LP	1 and 2	2 and 7	30	1-Level:2802-Level:209	1-Level:2652-Level:180	1-Level:CDR: 44.5ACDF: 43.92-Level:CDR: 47.1ACDF: 47.3
Guyer 2025²²	Simplify	1	5	10^b	150	117	CDR: 43ACDF: 44.1
Garrido 2010⁵²	Bryan	1	4	1	21	26	CDR: 40ACDF: 43.3
Riina 2008⁵³	Prestige ST	1	2	1	10	9	CDR: 40.8ACDF: 38.1
Sasso 2007⁵⁴	Bryan	1	2	3	56	59	CDR: 42.5ACDF: 46.1
Gornet 2019⁵⁵	Prestige LP	2	10	NA	209	180	CDR: 47.1ACDF: 47.6
Loumeau 2016⁵⁶	Prodisc C	1	7	1	22	22	CDR: 42.1^aACDF: 43.5^a
Jackson 2016⁵⁷	Mobi-C	1 and 2	5	24	1-Level:1792-Level:234	1-Level:812-Level:105	1-Level:CDR: 43.3^aACDF: 44^a2-Level:CDR: 45.3^aACDF: 46.2^a
Loidolt 2016⁵⁸	Bryan	1	10	30	242	221	CDR: 44.4ACDF: 44.7
Ghobrial 2019⁵⁹	Bryan	1	10	30	242	221	CDR: 44.4^aACDF: 44.7^a
Anderson 2008⁶⁰	Bryan	1	2	31	242	221	CDR: 44.4^aACDF: 44.7^a
Hacker 2005⁶¹	Bryan	1	2	1	22	24	CDR: 44.4^aACDF: 44.7^a
Nunley 2020⁶²	Mobi-C	1 and 2	7	NA	1-Level:1642-Level:225	1-Level:812-Level:105	1-Level:CDR: 43.3^aACDF: 44^a2-Level:CDR: 45.3^aACDF: 46.2^a
Hisey 2015⁶³	Mobi-C	1	5	23	164	81	CDR: 43.3^aACDF: 44^a
Delamarter 2013⁶⁴	Prodisc-C	1	5	13	103	106	CDR: 42.1^aACDF: 43.5^a
Phillips 2021⁶⁵	M6-C	1	2	23	160	189	CDR: 43.6ACDF: 44.7
Phillips 2024⁶⁶	M6-C	1	5	23	160	189	CDR: 43.6ACDF: 44.7
Davis 2014⁶⁷	Mobi-C	2	3	24	234	105	CDR: 43.3ACDF: 44
Guyer 2021⁶⁸	Simplify	1	2	16	150	117	CDR: 43ACDF: 44.1
Coric 2022²³	Simplify	2	2	18	182	170	CDR: 49.3ACDF: 47.5

^aFrom prior study.

^bbased on listed Principal Investigators in Acknowledgments.

To generate Kaplan–Meier–style survival curves from aggregate data, patient-level event times were reconstructed from the published discrete survival probabilities using the algorithm described by Guyot et al (2012)²² for individual patient data (IPD) reconstruction from published Kaplan–Meier curves. In cases where reported survival probabilities showed non-monotonic trends (ie, survival increasing over time), a monotonicity constraint was applied by replacing each value with the cumulative minimum of all preceding survival probabilities. This ensured biologically plausible curves and addressed potential artefacts arising from small sample sizes or reporting variability. For each surgical level (1-level, 2-level) and procedure type (CDR, ACDF), pooled FDA survival probabilities were calculated as weighted means, with weights proportional to the number at risk in each trial.

For comparative analyses, hazard ratios at each follow-up interval were calculated from survival probabilities using the formula: HR (t) = −log SPD (t)/−log SFDA(t). While these values do not represent Cox regression–derived hazard ratios, they provide a consistent relative measure of survival differences between FDA and PD cohorts at discrete time points. Statistical significance of differences in event rates between FDA and PD cohorts at each follow-up interval was assessed using Pearson’s chi-square test when all expected cell counts were ≥5, and Fisher’s exact test otherwise. A two-sided P value <0.05 was considered statistically significant. All analyses were conducted separately for each surgical level and procedure type. Survival curves were plotted for visual comparison, and numerical results including HR values and corresponding P values, were tabulated.

Result

A total of 277 146 ACDF and 25 957 CDR patients meeting eligibility criteria were identified in PD. Of these, 1-level procedures accounted for 174 135 ACDF and 21 995 CDR cases, while 2-level procedures included 103 011 ACDF and 3962 CDR cases (Table 2). Additionally, 897 studies were retrieved through database searches; following removal of duplicates and screening by title, abstract, and full text, 44 studies were included. Two additional supplement studies on Simplify device^23,24 from Google Scholar, not identified by the original database search, were also screened for data collection and analysis because of their approval from the FDA trial for commercial distribution (Tables 3 and 4).

Table 4.

Index And Adjacent Segment Surgery Event in FDA Trials Patient Cohort.

Study name^a	F/up period	Level	Index segment surgeries (n (%))		Adjacent segment surgeries (n (%))		Both levels^b (n (%))
Study name^a	F/up period	Level	CDR	ACDF	CDR	ACDF	CDR	ACDF
Mummaneni 2007	2	1	5	22	3	9	-	-
Burkus 2010	5	1	11	29	8	13	4	6
Burkus 2014	7	1	11	29	11	24	3	14
	2	1	9	19	-	-	-	-
Murrey 2009	2	1	2	9	0	1	-	-
Delamarter 2010	4	1	3	12	-	6	-	6
Zigler 2013	5	1	3	8	-	6	-	2
Janssen 2015	7	1	6	16	6	13	-	-
Heller 2009	2	1	6	8	-	-	-	-
Sasso 2007	2	1	0	2	2	2	-	-
Sasso 2011	2	1	6	8^c	6^c	5	-	-
	4	1	9	10^c	10^c	9	-	-
Sasso 2017	10	1	0	0	1	6	-	-
Lavelle 2019	10	1	5	6	12	16	-	-
Phillips 2013	2	1	10	10	2	0	1	0
Phillips 2015	5	1	17	5	0	17	-	-
	7	1	18	5	1	19	1	0
Hisey 2014	2	1	2	5	^d	^e	-	-
Hisey 2015	4	1	5	8	2	3	1	2
Radcliff 2017	7	1	5	10^f	6	11	-	-
	7	2	10	17^g	10	12	-	-
Davis 2013	2	2	7	12	2	-^h	-	-
Davis 2015	4	2	9	16	-	-	-	-
Radcliff 2016	5	2	9	17	-	-	-	-
Vaccaro 2013	2	1	6	14	4	2	-	-
Vacarro 2018	7	1	10	22	10	23	0	16
Gornet 2017	2	2	5	15	5	6	-	-
Gornet 2016	7	1	18	29	27	22	-	-
Gornet 2019	2	1	14	19	6	10	-	-
	5	1	17	27	23	20	-	-
	7	1	18	29	27	22	-	-
	10	1	27	-	34	-	-	-
Lanman 2017	7	2	8	22	12	17	-	-
Gornet 2019	2	1	14	19	6	10	-	-
	2	2	5	15	5	6	-	-
	7	1	18	29	27	22	-	-
	7	2	8	22	12	17	-	-
Guyer 2025	5	1	6	11	3ⁱ	7^j	3	7
Garrido 2010	4	1	0	2	1	4	0	1
Riina 2008	2	1	-	-	-	1	-	-
Sasso 2007	2	1	0	2	3	2	-	-
Gornet 2019	10	2	9	27	16	24	-	-
Loumeau 2016	7	1	0	2	0	4	-	-
Jackson 2016	5	1	4	5	2	4	2	5
	5	2	9	10	6	3	2	9
Loidolt 2016	10	1	14	20	22	32	-	-
Ghobrial 2019	10	1	-	-	22	32	-	-
	7	1	-	-	-	-	-	-
Anderson 2008	2	1	7	10	7	9	1	2
Hacker 2005	2	1	-	-	1	-	-	-
Nunley 2020	7	1	-	-	7	12	-	-
	7	1	-	-	10	12	-	-
Hisey 2015	5	1	5	8	3	6	-	-
Delamarter 2013	5	1	3	8	2	9	2	4
Phillips 2021	2	1	3	8	0	1	-	-
Phillips 2024	5	1	3	3	2	7	-	-
Davis 2014	3	2	7	14	-	-	-	-
Guyer 2021	2	1	1	4	0	2	2	-
Coric 2022	2	2	2	4	13	2^k	2	-

^aSome patients had more than 1 subsequent surgery.

^bRepresent subsequent surgery involving both index and adjacent segments.

^cSome secondary procedures were involved with both index and adjacent levels, and they were counted for index level only in this study.

^dNo reported cases of adjacent segment procedure.

^eHigher rates of adjacent segment degeneration, but no specific numbers were provided for actual adjacent segment surgeries.

^fThe adjusted number of secondary index segment procedure is 6.2%.

^gThe adjusted number of secondary index segment procedure is 10.5%.

^hACDF patients likely had adjacent-level involvement in some removals (eg, fusion extensions), but exact numbers are not provided in trial.

ⁱCase 1: Index C6/7 + adjacent C6 -T2 was excluded from the count because of thoracic level involvement.

^jCase 9: Adjacent level involving C7/T1 (original index level: C6/7) was excluded from the count because of thoracic level involvement.

^kOne adjacent segment intervention was excluded because it was at T1.

Abbreviation: F/up = Follow-up.

A comparison of survival probabilities between FDA IDE trial cohorts and PD cohorts at 2-, 4-, 5-, 7-, and 10-year follow-up intervals is presented in Table 5. For 1-level ACDF, PD cohorts demonstrated significantly higher survival probabilities at 2 years (HR = 0.48, P < 0.001), 5 years (HR = 0.78, P = 0.038), 7 years (HR = 0.38, P < 0.001), and 10 years (HR = 0.37, P < 0.001). No significant difference was observed at 4 years (HR = 0.70, P = 0.220). For 1-level CDR, PD cohorts also showed a modest survival advantage at 2 years (HR = 0.73, P = 0.002), 7 years (HR = 0.56, P < 0.001), and 10 years (HR = 0.64, P = 0.050), whereas no significant difference was detected at 4 years (HR = 1.07, P = 0.494) or 5 years (HR = 0.88, P = 0.112). In the 2-level ACDF cohort, survival probabilities were similar at 2 years (HR = 0.98, P = 0.645), but PD cohorts demonstrated significantly higher survival at 5 years (HR = 0.31, P < 0.001) and 7 years (HR = 0.36, P < 0.001). For 2-level CDR, survival rates remained high and comparable between the 2 cohorts, with no statistically significant differences at 2 years (HR = 0.94, P = 0.787), 5 years (HR = 0.69, P = 0.093), or 7 years (HR = 0.67, P = 0.211). Data for the PD cohort was not available at the 10-year follow-up for both 2-level ACDF and CDR due to the small sample size.

Table 5.

Survival Probability And Hazard Ratio.

F/up period	Cohort*	FDA (survival probability)	PD (survival probability)	HR	P-value
2-year	1-Level CDR	0.958	0.969	0.8	0.002
	2-Level CDR	0.964	0.966	0.9	0.8
	1-Level ACDF	0.921	0.961	0.5	<0.001
	2-Level ACDF	0.955	0.956	0.97	0.6
4-year	1-Level CDR	0.957	0.954	1.1	0.5
4-year	1-Level ACDF	0.921	0.944	0.7	0.2
5-year	1-Level CDR	0.942	0.949	0.9	0.1
	2-Level CDR	0.928	0.950	0.7	0.09
	1-Level ACDF	0.921	0.938	0.8	0.04
	2-Level ACDF	0.790	0.930	0.3	<0.001
7-year	1-Level CDR	0.893	0.939	0.55	<0.001
	2-Level CDR	0.919	0.945	0.7	0.2
	1-Level ACDF	0.820	0.928	0.4	<0.001
	2-Level ACDF	0.790	0.919	0.35	<0.001
10-year	1-Level CDR	0.893	0.930	0.6	0.05
	1-Level ACDF	0.791	0.916	0.4	<0.001
	2-Level ACDF	0.729	-	-	-

*Some patients had more than 1 surgical procedure. Abbreviations: F/up = Follow-up period; FDA = Food and Drug Administration; PD = PearlDiver; HR = Hazar ratio.

Survival Analysis

Level 1 ACDF

In the Level 1 ACDF cohort, the PD group consistently demonstrated higher survival probabilities compared to the FDA IDE cohort across most follow-up intervals. At year 2, survival was 96% in the PD group vs 92% in the FDA group (P < 0.001). This difference persisted at year 5 (PD: 94% vs FDA: 92%, P = 0.038) and became more pronounced at years 7 and 10, where PD maintained survival above 92%, while the FDA group declined to 82% at year 10 (P < 0.001). The separation between curves widened substantially after year 7, highlighting a sustained survival advantage for the PD cohort at longer follow-up durations. (Figure 2).

Figure 2.

Kaplan–Meier Survival Curve (ACDF, Level 1)

Level 2 ACDF

In the Level 2 ACDF cohort, the PD group showed consistently higher survival probabilities than the FDA IDE cohort at mid- and long-term follow-up. At year 2, both groups had nearly identical survival (PD: 95.6% vs FDA: 95.5%, P = 0.645). However, by year 5, the difference became striking, with PD maintaining a survival probability of 93% compared to only 79% in the FDA cohort (P < 0.001). This trend continued at year 7, where survival remained higher in the PD group (92% vs 79% in FDA, P < 0.001). (Figure 3).

Figure 3.

Kaplan–Meier Survival Curve (ACDF, Level 2)

Level 1 CDR

In the Level 1 CDR cohort, both the FDA IDE and PD groups demonstrated high survival probabilities throughout follow-up, but the PD group consistently maintained a modest survival advantage. At year 2, survival was 97% in the PD cohort compared to 96% in the FDA group (P = 0.002). Differences narrowed at years 4 and 5, where survival remained above 94% in both groups and no statistically significant differences were observed. However, by year 7, the PD cohort again demonstrated significantly higher survival (94% vs 89% in FDA, P < 0.001). At year 10, survival declined further in the FDA group (89%) compared with 93% in the PD cohort (P = 0.050). (Figure 4).

Figure 4.

Kaplan–Meier Survival Curve (CDR, Level 1)

Level 2 CDR

In the Level 2 CDR cohort, survival probabilities remained high in both FDA IDE and PD groups throughout the follow-up period, with no statistically significant differences at any time point. At year 2, both groups demonstrated nearly identical survival (97%). By year 5, PD maintained survival at 95% compared to 93% in the FDA group (P = 0.093), and this modest difference persisted at year 7 (95% vs 92%, P = 0.211). At year 10, survival further declined in the FDA group (88%), while PD remained at 95%, though statistical testing was not available due to missing PD data. (Figure 5).

Figure 5.

Kaplan–Meier Survival Curve (CDR, Level 2)

Discussion

Our study aimed to compare the long-term outcomes of CDR and ACDF using real-world data from the PD database and FDA IDE trials. The results highlight notable differences in the risk of subsequent surgeries between these 2 datasets for both procedures. In our analysis of the CDR group, real-world data from PD showed that the risks of subsequent surgeries were generally similar to those observed in controlled trials, but with some variations across different follow-up periods. For instance, at the 7-year follow-up, the subsequent surgery rate for CDR was 6.13% in PD data compared to 10.72% in FDA trials. However, only 1-level intervention at 2-, 7-, and 10-year timepoints was able to reach statistical significance on survival analysis and observed findings for 2-level intervention could be by chance. This suggests that while CDR performs similarly in real-world settings as in controlled trials, there may be minor differences in outcomes due to variations in patient populations or clinical practices. In contrast, the ACDF group demonstrated a significant discrepancy between real-world and controlled trial settings. The risks of subsequent surgeries were substantially lower in PD data compared to FDA trials across all follow-up periods on survival analysis. For example, at the 7-year follow-up, the subsequent surgery rate for ACDF was 7.24% in PD data vs 18.04% in FDA trials (HR: 0.4, P < 0.001). This indicates that ACDF outcomes in real-world settings may be more favorable than those reported in controlled trials, possibly due to better patient selection or improved surgical techniques not captured in older IDE trials. Additionally, postoperative fusion assessment in the FDA trials was performed by radiologists and included patient-reported outcome measures, reflecting greater scrutiny than typical clinical practice and likely contributing to the observed disparity in findings.

A systematic review by Toci et al underscored the advantages of CDR in reducing ASD and enhancing clinical outcomes, findings further supported by large-scale epidemiological evidence from Singh et al.^8,69 In their cohort analysis of 433 660 patients, CDR was associated with significantly reduced rates of anterior revision (3.35% vs 4.96%, P < .001) and posterior fusion (0.79% vs 2.14%, P < .001) relative to ACDF. However, our study uniquely extends these insights by demonstrating that such benefits are also evident in real-world settings, albeit with more modest effect sizes when compared to those observed in controlled trials. This discrepancy may stem from differences in patient demographics, surgical indications, or institutional practices inherent to real-world data as opposed to the tightly controlled environments of IDE trials. Notably, it is plausible that patients presenting with more complex pathology were preferentially selected for ACDF, potentially introducing baseline disparities that attenuate the observable benefit of CDR over ACDF in controlled trials.

Tuchman et al, in a retrospective comparison of single-level CDR and ACDF, reported no significant difference in reoperation rates.⁷⁰ Similarly, Kelly et al. noted that while CDR reduced immediate postoperative readmissions and the need for early revision surgeries, it did not offer significant advantages over ACDF in terms of long-term complication rates.⁷¹ However, their study was limited by its reliance on a state-specific nonfederal database that excluded revisions occurring in federal institutions, potentially underestimating the true complication burden.

Further reinforcing this point, Paek et al, in a 10-year retrospective analysis using the Statewide Planning and Research Cooperative System (SPARCS) database, evaluated outcomes for patients undergoing single-level CDR (n = 835) and ACDF (n = 6615).⁷² They found no significant difference in revision surgery risk between the 2 cohorts. Nevertheless, SPARCS is limited to data from New York State and may not capture patients who underwent revisions outside the state, thereby restricting the generalizability of the findings.

Importantly, our study addresses several of these limitations through the use of a nationally representative dataset with a broader capture of subsequent procedures, enhancing the external validity of our conclusions. By leveraging real-world evidence on a large scale, we provide a comprehensive and clinically relevant assessment of CDR and ACDF outcomes that complements and contextualizes existing trial data. Our study contributes to the existing literature by demonstrating that while the effectiveness of CDR observed in controlled trials is largely supported in real-world settings, ACDF outcomes appear even more favourable in practice than previously reported in trials. The FDA’s post-approval studies (PAS) program highlights the need for continued long-term follow-up to ensure the safety and efficacy of these devices.⁷³ This validation is essential for guiding clinical decision-making, ensuring the long-term safety and efficacy of both procedures and helping clinicians select the most appropriate treatment based on individual patient needs and anatomical considerations.

Strength and Limitations

Although this study provides meaningful findings, several limitations should be acknowledged. First, the use of insurance claims data may introduce bias due to potential inaccuracies in coding and inconsistencies in patient follow-up. Additionally, the database only offers aggregate-level information, which limits the ability to assess detailed clinical factors such as spinal alignment before and after surgery. Furthermore, the constraints of CPT coding and the structure of the database restrict the ability to fully understand the indications for surgery, making it challenging to identify whether follow-up procedures were related to adjacent or index-level issues. Another important limitation is the inability to differentiate between devices on PD, as the database lacks specific CPT or ICD-9/10 codes for individual devices, which may obscure device-specific outcomes and trends. Finally, while this study compares FDA IDE trial results with real-world outcomes, we did not adjust for baseline population differences between the more narrowly selected trial participants and the broader, more heterogeneous real-world cohort. Nevertheless, the study highlights the value of real-world evidence in assessing surgical outcomes. Importantly, the use of the large PD dataset enhances the statistical strength of the analysis, allowing for meaningful comparisons between CDR and ACDF. By examining real-world data alongside results from IDE trials, this research offers a broader perspective on the performance of these procedures in both clinical and everyday practice settings.

Conclusion

In conclusion, our study highlights that while CDR performs similarly in real-world settings as in controlled trials for 1-level intervention, ACDF outcomes are more favourable in real-world settings compared to controlled trials. The subsequent surgery risks for ACDF were significantly lower in real-world data compared to FDA trials, suggesting improved outcomes in diverse patient populations. This validation is essential for guiding clinical decisions and ensuring the long-term safety and efficacy of these surgical procedures. Our findings support the continued use of CDR as a viable alternative to ACDF for select patients, however, further research exploring the difference in rate of index and adjacent segment surgeries in the real world is needed to understand the factors contributing to these differences and to optimize patient selection for each procedure. Ultimately, this study underscores the importance of real-world data in complementing controlled trials to provide a comprehensive understanding of surgical outcomes.

Supplemental Material

Supplemental Material - Long-Term Outcomes of Cervical Disc Replacement and Anterior Cervical Discectomy and Fusion: A Review of FDA IDE Trials With Real-World Comparison

Supplemental Material for Long-Term Outcomes of Cervical Disc Replacement and Anterior Cervical Discectomy and Fusion: A Review of FDA IDE Trials With Real-World Comparison by Ali Issani, William J. Karakash, Henry Avetisian, Zeeshan Ahsan, Dil Patel, David Riopelle, Kevin Kashanchi, Matthew Gallo, Raymond J. Hah, Amyn Malik, Ram K. Alluri, John C. Liu, Jeffrey C. Wang in Global Spine Journal

Footnotes

ORCID iDs

Ali Issani

William J. Karakash

David Riopelle

Raymond J. Hah

Ram K. Alluri

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ali Issani, William J. Karakash, Henry Avetisian, Zeeshan Ahsan, Dil Patel, David Riopelle, Kevin Kashanchi and Matthew Gallo have nothing to disclose. Jeffrey C. Wang has received intellectual property royalties from Zimmer Biomet, NovApproach, SeaSpine, and DePuy Synthes, and stock options from Bone Biologics, Electrocore, PearlDiver, and Surgitech. Raymond J. Hah has received grant funding from SI bone, consulting fees from NuVasive, and support from the North American Spine Society to attend meetings. Amyn Malik was employed by Analysis Group, Inc as a consultant between 2022 and 2024. Ram K. Alluri has received grant funding from NIH, consulting fees and stock options from HIA Technologies, and payment from Eccential Robotics for lectures and presentations. John C. Liu has received consulting fees from vision, illuminant surgical, Nov approach and Spark spine, and support for attending meetings and/or travel from Global spine congress and NASS summer meeting.

Data Availability Statement

Data is not publicly available but can be available upon request.*

Supplemental Material

Supplemental material for this article is available online.

Appendix

References

Nouri

Tetreault

Singh

Karadimas

Fehlings

. Degenerative cervical myelopathy: epidemiology, genetics, and pathogenesis. Spine. 2015;40(12):E675-E693.

Korinth

. Treatment of cervical degenerative disc disease - current status and trends. Zentralbl Neurochir. 2008;69(3):113-124.

Mazas

Benzakour

Castelain

Damade

Ghailane

Gille

. Cervical disc herniation: which surgery? Int Orthop. 2019;43(4):761-766.

Prestige

. Cervical disc. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=353100

Saifi

Fein

Cazzulino

, et al. Trends in resource utilization and rate of cervical disc arthroplasty and anterior cervical discectomy and fusion throughout the United States from 2006 to 2013. Spine J. 2018;18(6):1022-1029. doi:10.1016/j.spinee.2017.10.072

Niedzielak

Ameri

Emerson

Vakharia

Roche

JPt

. Trends in cervical disc arthroplasty and revisions in the medicare database. J Spine Surg. 2018;4(3):522-528.

Ratnasamy

Rudisill

Maloy

Grauer

. Cervical disc arthroplasty usage has leveled out from 2010 to 2021. Spine. 2023;48(20):E342-E348.

Singh

Balmaceno-Criss

Anderson

, et al. Anterior cervical discectomy and fusion versus cervical disc arthroplasty: an epidemiological review of 433,660 surgical patients from 2011 to 2021. Spine J. 2024;24(8):1342-1351.

Mobi-C cervical disc prosthesis (two-level indication). Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110009

10.

Mobi-C cervical disc prosthesis (one-level indication). Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110002

11.

Simplify cervical artificial disc. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200022S003A.pdf

12.

Prestige cervical disc system. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P060018

13.

ProDisc-C total disc replacement. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P070001

14.

Bryan cervical disc prosthesis. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P060023

15.

Nuvasive PCM cervical disc system. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100012

16.

Secure-C artificial cervical disc. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100003

17.

M6-C artificial cervical disc. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170036

18.

Bydon

Michalopoulos

Alvi

Goyal

Abode-Iyamah

. Cervical total disc replacement: Food and drug administration-approved devices. Neurosurg Clin. 2021;32(4):425-435.

19.

Hines

Lurie

Wolfe

. Left to their own devices: breakdowns in United States medical device premarket review. PLoS Med. 2010;7(7):e1000280. doi:10.1371/journal.pmed.1000280

20.

Lauer

Barker

Solano

Dubin

. FDA device regulation. Mo Med. 2017;114(4):283-288.

21.

Rathi

Krumholz

Masoudi

Ross

. Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011. JAMA. 2015;314(6):604-612.

22.

Guyot

Ades

Ouwens

Welton

. Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9

23.

Guyer

Bae

Coric

, et al. Five-year Follow-up of a prospective food and drug administration investigational device exemption trial evaluating a PEEK-on-Ceramic cervical disk replacement. Spine. 2025;50(1):1-9. doi:10.1097/BRS.0000000000005123

24.

Coric

Guyer

Bae

, et al. Prospective, multicenter study of 2-level cervical arthroplasty with a PEEK-on-ceramic artificial disc. J Neurosurg Spine. 2022;37(3):357-367. doi:10.3171/2022.1.SPINE211264

25.

Mummaneni

Burkus

Haid

Traynelis

Zdeblick

. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine. 2007;6(3):198-209. doi:10.3171/spi.2007.6.3.198

26.

Burkus

Haid

Traynelis

Mummaneni

. Long-term clinical and radiographic outcomes of cervical disc replacement with the prestige disc: results from a prospective randomized controlled clinical trial. J Neurosurg Spine. 2010;13(3):308-318. doi:10.3171/2010.3.SPINE09513

27.

Burkus

Traynelis

Haid

Jr Mummaneni

. Clinical and radiographic analysis of an artificial cervical disc: 7-Year follow-up from the prestige prospective randomized controlled clinical trial: clinical article. J Neurosurg Spine. 2014;21(4):516-528. doi:10.3171/2014.6.SPINE13996

28.

Murrey

Janssen

Delamarter

, et al. Results of the prospective, randomized, controlled multicenter food and drug administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. Spine J. 2009;9(4):275-286. doi:10.1016/j.spinee.2008.05.006

29.

Delamarter

Murrey

Janssen

, et al. Results at 24 months from the prospective, randomized, multicenter investigational device exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. SAS J. 2010;4(4):122-128. doi:10.1016/j.esas.2010.09.001

30.

Zigler

Delamarter

Murrey

Spivak

Janssen

. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a food and drug administration study. Spine. 2013;38(3):203-209. doi:10.1097/BRS.0b013e318278eb38

31.

Janssen

Zigler

Spivak

Delamarter

Darden

Kopjar

. ProDisc-C total disc replacement versus anterior cervical discectomy and fusion for single-level symptomatic cervical disc disease: seven-year Follow-up of the prospective randomized U.S. food and drug administration investigational device exemption study. J Bone Joint Surg Am. 2015;97(21):1738-1747. doi:10.2106/JBJS.N.01186

32.

Heller

Sasso

Papadopoulos

, et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. Spine. 2009;34(2):101-107. doi:10.1097/BRS.0b013e31818ee263

33.

Sasso

Smucker

Hacker

Heller

. Artificial disc versus fusion: a prospective, randomized study with 2-year follow-up on 99 patients. Spine. 2007;32(26):2933-2942. doi:10.1097/BRS.0b013e31815d0034

34.

Sasso

Anderson

Riew

Heller

. Results of cervical arthroplasty compared with anterior discectomy and fusion: four-year clinical outcomes in a prospective, randomized controlled trial. J Bone Joint Surg Am. 2011;93(18):1684-1692. doi:10.2106/JBJS.J.00476

35.

Sasso

Smucker

Sasso

. Long-term clinical outcomes of cervical disc arthroplasty: a prospective, randomized, controlled trial. Spine. 2017;42(4):209-216. doi:10.1097/BRS.0000000000001746

36.

Lavelle

Riew

Levi

Florman

. Ten-year outcomes of cervical disc replacement with the BRYAN cervical disc: results from a prospective, randomized, controlled clinical trial. Spine. 2019;44(9):601-608. doi:10.1097/BRS.0000000000002907

37.

Phillips

Lee

Geisler

, et al. A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. 2-year results from the US FDA IDE clinical trial. Spine. 2013;38(15):E907-E918. doi:10.1097/BRS.0b013e318296232f

38.

Phillips

Geisler

Gilder

Reah

Howell

McAfee

. Long-term outcomes of the US FDA IDE prospective, randomized controlled clinical trial comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. Spine. 2015;40(10):674-683. doi:10.1097/BRS.0000000000000869

39.

Hisey

Bae

Davis

, et al. Multi-center, prospective, randomized, controlled investigational device exemption clinical trial comparing Mobi-C cervical artificial disc to anterior discectomy and fusion in the treatment of symptomatic degenerative disc disease in the cervical spine. Int J Spine Surg. 2014;8:7. doi:10.14444/1007

40.

Hisey

Bae

Davis

, et al. Prospective, randomized comparison of cervical total disk replacement versus anterior cervical fusion: results at 48 months Follow-up. J Spinal Disord Tech. 2015;28(4):E237-E243. doi:10.1097/BSD.0000000000000185

41.

Radcliff

Davis

Hisey

, et al. Long-term evaluation of cervical disc arthroplasty with the Mobi-C© cervical disc: a randomized, prospective, multicenter clinical trial with seven-year Follow-up. Int J Spine Surg. 2017;11(4):31. doi:10.14444/4031

42.

Davis

Kim

Hisey

, et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial: clinical article. J Neurosurg Spine. 2013;19(5):532-545. doi:10.3171/2013.6.SPINE12527

43.

Davis

Nunley

Kim

, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. J Neurosurg Spine. 2015;22(1):15-25. doi:10.3171/2014.7.SPINE13953

44.

Radcliff

Coric

Albert

. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial [published correction appears in J Neurosurg Spine. 2016 Aug;25(2):280. doi: 10.3171/2016.3.SPINE15824a]. J Neurosurg Spine. 2016;25(2):213-224. doi:10.3171/2015.12.SPINE15824

45.

Vaccaro

Beutler

Peppelman

, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. Spine. 2013;38(26):2227-2239. doi:10.1097/BRS.0000000000000031

46.

Vaccaro

Beutler

Peppelman

, et al. Long-term clinical experience with selectively constrained SECURE-C cervical artificial disc for 1-Level cervical disc disease: results from seven-year Follow-Up of a prospective, randomized, controlled investigational device exemption clinical trial. Int J Spine Surg. 2018;12(3):377-387. doi:10.14444/5044

47.

Gornet

Lanman

Burkus

, et al. Cervical disc arthroplasty with the prestige LP disc versus anterior cervical discectomy and fusion, at 2 levels: results of a prospective, multicenter randomized controlled clinical trial at 24 months. J Neurosurg Spine. 2017;26(6):653-667. doi:10.3171/2016.10.spine16264

48.

Gornet

Kenneth Burkus

Shaffrey

Nian

Harrell

. Cervical disc arthroplasty with prestige LP disc versus anterior cervical discectomy and fusion: seven-year outcomes. Int J Spine Surg. 2016;10:24. doi:10.14444/3024

49.

Gornet

Burkus

Shaffrey

Schranck

Copay

. Cervical disc arthroplasty: 10-year outcomes of the prestige LP cervical disc at a single level. J Neurosurg Spine. 2019;31(3):317-325. doi:10.3171/2019.2.SPINE1956

50.

Lanman

Burkus

Dryer

Gornet

McConnell

Hodges

. Long-term clinical and radiographic outcomes of the prestige LP artificial cervical disc replacement at 2 levels: results from a prospective randomized controlled clinical trial. J Neurosurg Spine. 2017;27(1):7-19. doi:10.3171/2016.11.SPINE16746

51.

Gornet

Lanman

Burkus

, et al. One-level versus 2-Level treatment with cervical disc arthroplasty or fusion: outcomes up to 7 years. Int J Spine Surg. 2019;13(6):551-560. doi:10.14444/6076

52.

Garrido

Taha

Sasso

. Clinical outcomes of Bryan cervical disc arthroplasty a prospective, randomized, controlled, single site trial with 48-month follow-up. J Spinal Disord Tech. 2010;23(6):367-371. doi:10.1097/BSD.0b013e3181bb8568

53.

Riina

Patel

Dietz

Hoskins

Trammell

Schwartz

. Comparison of single-level cervical fusion and a metal-on-metal cervical disc replacement device. Am J Orthoped. 2008;37(4):E71-E77.

54.

Sasso

Smucker

Hacker

Heller

. Clinical outcomes of BRYAN cervical disc arthroplasty: a prospective, randomized, controlled, multicenter trial with 24-month follow-up. J Spinal Disord Tech. 2007;20(7):481-491. doi:10.1097/BSD.0b013e3180310534

55.

Gornet

Lanman

Burkus

, et al. Two-level cervical disc arthroplasty versus anterior cervical discectomy and fusion: 10-year outcomes of a prospective, randomized investigational device exemption clinical trial. J Neurosurg Spine. 2019;31(4):508-518. doi:10.3171/2019.4.spine19157

56.

Loumeau

Darden

Kesman

, et al. A RCT comparing 7-year clinical outcomes of one level symptomatic cervical disc disease (SCDD) following ProDisc-C total disc arthroplasty (TDA) versus anterior cervical discectomy and fusion (ACDF). Eur Spine J. 2016;25(7):2263-2270. doi:10.1007/s00586-016-4431-6

57.

Jackson

Davis

Hoffman

, et al. Subsequent surgery rates after cervical total disc replacement using a Mobi-C Cervical Disc Prosthesis versus anterior cervical discectomy and fusion: a prospective randomized clinical trial with 5-year follow-up. J Neurosurg Spine. 2016;24(5):734-745. doi:10.3171/2015.8.SPINE15219

58.

Loidolt

Kurra

Riew

Levi

Florman

Lavelle

. Comparison of adverse events between cervical disc arthroplasty and anterior cervical discectomy and fusion: a 10-year follow-up. Spine J. 2021;21(2):253-264. doi:10.1016/j.spinee.2020.10.013

59.

Ghobrial

Lavelle

Florman

Riew

Levi

. Symptomatic adjacent level disease requiring surgery: analysis of 10-Year results from a prospective, randomized, clinical trial comparing cervical disc arthroplasty to anterior cervical fusion. Neurosurgery. 2019;84(2):347-354. doi:10.1093/neuros/nyy118

60.

Anderson

Sasso

Riew

. Comparison of adverse events between the Bryan artificial cervical disc and anterior cervical arthrodesis. Spine. 2008;33(12):1305-1312. doi:10.1097/BRS.0b013e31817329a1

61.

Hacker

. Cervical disc arthroplasty: a controlled randomized prospective study with intermediate follow-up results. Invited submission from the joint section meeting on disorders of the spine and peripheral nerves, March 2005 [published correction appears in J Neurosurg Spine. 2006 Feb;4(2):189]. J Neurosurg Spine. 2005;3(6):424-428. doi:10.3171/spi.2005.3.6.0424

62.

Nunley

Kerr

Cavanaugh

, et al. Adjacent segment pathology after treatment with cervical disc arthroplasty or anterior cervical discectomy and fusion, part 2: clinical results at 7-Year Follow-Up. Int J Spine Surg. 2020;14(3):278-285. doi:10.14444/7037

63.

Hisey

Zigler

Jackson

, et al. Prospective, randomized comparison of one-level Mobi-C cervical total disc replacement vs. anterior cervical discectomy and fusion: results at 5-year Follow-up. Int J Spine Surg. 2016;10:10. doi:10.14444/3010

64.

Delamarter

Zigler

. Five-year reoperation rates, cervical total disc replacement versus fusion, results of a prospective randomized clinical trial. Spine. 2013;38(9):711-717. doi:10.1097/BRS.0b013e3182797592

65.

Phillips

Coric

Sasso

, et al. Prospective, multicenter clinical trial comparing M6-C compressible six degrees of freedom cervical disc with anterior cervical discectomy and fusion for the treatment of single-level degenerative cervical radiculopathy: 2-year results of an FDA investigational device exemption study. Spine J. 2021;21(2):239-252. doi:10.1016/j.spinee.2020.10.014

66.

Phillips

Coric

Sasso

, et al. Prospective, multicenter clinical trial comparing the M6-C compressible cervical disc with anterior cervical discectomy and fusion for the treatment of single-level degenerative cervical radiculopathy: 5-year results of an FDA investigational device exemption study. Spine J. 2024;24(2):219-230. doi:10.1016/j.spinee.2023.10.020

67.

Davis

Nunley

Kim

, et al. Two-level total disc replacement with Mobi-C(r) over 3-years. Coluna/Columna. 2014;13(2):97-103. doi:10.1590/s1808-18512014130200452

68.

Guyer

Coric

Nunley

, et al. Single-Level cervical disc replacement using a PEEK-on-Ceramic implant: results of a multicenter FDA IDE trial with 24-Month Follow-up. Int J Spine Surg. 2021;15(4):633-644. doi:10.14444/8084

69.

Toci

Canseco

Patel

, et al. The incidence of adjacent segment pathology after cervical Disc Arthroplasty compared with anterior cervical discectomy and fusion: a systematic review and meta-analysis of randomized clinical trials. World Neurosurg. 2022;160:e537-e548. doi:10.1016/j.wneu.2022.01.072

70.

Tuchman

Chen

Walker

Kanim

Bae

Skaggs

. Is single-level cervical disc arthroplasty associated with a lower reoperation rate than anterior cervical discectomy and fusion? J Neurosurg Spine. 2024;40(3):282-290.

71.

Kelly

Eliasberg

Riley

Ajiboye

Soo Hoo

. Reoperation and complications after anterior cervical discectomy and fusion and cervical disc arthroplasty: a study of 52,395 cases. Eur Spine J. 2018;27(6):1432-1439.

72.

Paek

Zelenty

Dodo

, et al. Up to 10-year surveillance comparison of survivability in single-level cervical disc replacement versus anterior cervical discectomy and fusion in New York. J Neurosurg Spine. 2023;39(2):206-215.

73.

Rajan

Kramer

Kesselheim

. Medical device postapproval safety monitoring: where does the United States stand? Circ Cardiovasc Qual Outcomes. 2015;8(1):124-131.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB